| Imatinib | IC50 | 100.0 [1] |
| Sunitinib | IC50 | 10.0 [1] |
| Sunitinib | Ki | 4.0 [1] |
| Dasatinib | IC50 | 5.0 [1] |
| Staurosporine | IC50 | 4.5 [1] |
| Nilotinib | IC50 | 200.0 [1] |
| Cabozantinib | IC50 | 4.6 [1] |
| Foretinib | IC50 | 6.7 [1] |
| 4-Methyl-N-[3-methyl-5-(4-methylimidazol-1-yl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide | IC50 | 200.0 [1] |
| 4-Methyl-N-[3-(4-methylimidazol-1-yl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide | IC50 | 200.0 [1] |
| N-[3-Fluoro-5-(4-methylimidazol-1-yl)phenyl]-4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide | IC50 | 200.0 [1] |
| Bosutinib | IC50 | 32.0 [1], 132.0 [2], 181.0 [3], 2772.0 [4], 6313.0 [5] |
| Sorafenib | IC50 | 10.0 [1], 31.0 [2], 68.0 [3] |
| Ellipticine | IC50 | 200.0 [1], 10000.0 [2] |
| Dovitinib | IC50 | 1.0 [1], 1.1 [2], 3.0 [3], 48.3 [4] |
| Elliptinium | IC50 | 10.0 [1], 400.0 [2] |
| 9-Hydroxyellipticine | IC50 | 10.0 [1], 400.0 [2] |
| 9-Methoxyellipticine | IC50 | 300.0 [1], 500.0 [2], 600.0 [3], 800.0 [4] |
| 1-[4-(4-Aminothieno[2,3-d]pyrimidin-5-yl)phenyl]-3-(3-methylphenyl)urea | IC50 | 6.0 [1], 6.03 [2] |
| Datelliptium | IC50 | 10.0 [1], 300.0 [2], 450.0 [3] |
| Thienopyrimidine deriv. 11 | IC50 | 8.91 [1], 9.0 [2] |
| 1,3-Propanediamine, N,N-diethyl-N'-(9-methoxy-5-methyl-6H-pyrido(4,3-b)carbazol-1-yl)- | IC50 | 400.0 [1], 600.0 [2], 2000.0 [3], 2500.0 [4] |
| 6H-Pyrido(4,3-b)carbazol-9-ol, 1-((3-(diethylamino)propyl)amino)-5,11-dimethyl- | IC50 | 10.0 [1], 1200.0 [2], 1400.0 [3] |
| 9-Bromoellipticine | IC50 | 200.0 [1], 300.0 [2], 10000.0 [3] |
| N',N'-Diethyl-N-(2-methyl-6,15,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1,3(8),4,6,9,11(16),12,14-octaen-7-yl)propane-1,3-diamine | IC50 | 250.0 [1], 300.0 [2], 1900.0 [3], 2300.0 [4] |
| 4-(4-(5-Benzylpyrimidin-2-yl)piperazin-1-yl)quinazoline | IC50 | 316.0 [1], 699.0 [2], 2823.0 [3], 10000.0 [4] |
| Pazopanib | IC50 | 74.0 [1], 118.0 [2] |
| Vatalanib | IC50 | 620.0 [1], 700.0 [2], 730.0 [3] |
| Semaxanib | IC50 | 35.0 [1], 400.0 [2], 660.0 [3] |
| Ponatinib | IC50 | 1.7 [1], 4.9 [2] |
| Saracatinib | IC50 | 200.0 [1] |
| Linifanib | IC50 | 14.0 [1], 16.0 [2] |
| Osi-930 | IC50 | 10.0 [1], 29.0 [2], 80.0 [3] |
| 3-N-[4-(4-Morpholin-4-ylcyclohexyl)phenyl]-1-pyridin-2-yl-1,2,4-triazole-3,5-diamine | IC50 | 4.0 [1] |
| 3-N-[4-(4-Morpholin-4-ylcyclohexyl)phenyl]-1-pyridin-2-yl-1,2,4-triazole-3,5-diamine | Ki | 1.0 [1] |
| Thienopyrimidine deriv. 20 | IC50 | 21.88 [1], 22.0 [2] |
| Thienopyrimidine deriv. 24 | IC50 | 140.0 [1], 141.25 [2] |
| Thienopyrimidine deriv. 26 | IC50 | 19.0 [1], 19.05 [2] |
| Thienopyrimidine deriv. 88 | IC50 | 26.92 [1], 27.0 [2] |
| Thienopyrimidine deriv. 91 | IC50 | 38.0 [1], 38.02 [2] |
| Thienopyrimidine deriv. 93 | IC50 | 28.0 [1], 28.18 [2] |
| Thienopyrimidine deriv. 10 | IC50 | 67.61 [1], 68.0 [2] |
| Thienopyrimidine deriv. 13 | IC50 | 50.0 [1], 50.12 [2] |
| Thienopyrimidine deriv. 14 | IC50 | 19.0 [1], 19.05 [2] |
| Thienopyrimidine deriv. 15 | IC50 | 15.0 [1], 15.14 [2] |
| Thienopyrimidine deriv. 18 | IC50 | 33.0 [1], 33.11 [2] |
| Thienopyrimidine deriv. 19 | IC50 | 109.65 [1], 110.0 [2] |
| Thienopyrimidine deriv. 21 | IC50 | 28.84 [1], 29.0 [2] |
| Thienopyrimidine deriv. 23 | IC50 | 47.86 [1], 48.0 [2] |
| Thienopyrimidine deriv. 27 | IC50 | 173.78 [1], 175.0 [2] |
| Thienopyrimidine deriv. 28 | IC50 | 181.97 [1], 182.0 [2] |
| Thienopyrimidine deriv. 51 | IC50 | 158.49 [1], 160.0 [2] |
| Thienopyrimidine deriv. 52 | IC50 | 398.11 [1], 400.0 [2] |
| Thienopyrimidine deriv. 53 | IC50 | 930.0 [1], 933.25 [2] |
| Thienopyrimidine deriv. 59 | IC50 | 575.44 [1], 580.0 [2] |
| Thienopyrimidine deriv. 60 | IC50 | 794.33 [1], 800.0 [2] |
| Thienopyrimidine deriv. 79 | IC50 | 81.28 [1], 82.0 [2] |
| Thienopyrimidine deriv. 83 | IC50 | 954.99 [1], 960.0 [2] |
| Thienopyrimidine deriv. 85 | IC50 | 360.0 [1], 363.08 [2] |
| Thienopyrimidine deriv. 87 | IC50 | 810.0 [1], 812.83 [2] |
| Thienopyrimidine deriv. 90 | IC50 | 180.0 [1], 181.97 [2] |
| Thienopyrimidine deriv. 92 | IC50 | 53.7 [1], 54.0 [2] |
| Taxifolin | IC50 | 15700.0 [1], 21900.0 [2] |
| Ceritinib | IC50 | 1280.0 [1], 2855.0 [2] |
| Tandutinib | IC50 | 170.0 [1], 220.0 [2] |
| Pectolinarigenin | IC50 | 600.0 [1], 1500.0 [2] |
| Bms-777607 | IC50 | 144.0 [1], 500.0 [2] |
| JNJ-28312141 free base | IC50 | 5.0 [1], 41.0 [2] |
| 4-[2-(Butylamino)-5-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-7-yl]cyclohexan-1-ol | IC50 | 8.18 [1] |
| Tafetinib | IC50 | 2.4 [1], 5.0 [2] |
| 2-[2-[4-[4-(4-Tert-butylanilino)phenoxy]-6-methoxyquinolin-7-yl]oxyethylamino]ethanol | IC50 | 69.0 [1], 100.0 [2] |
| 3-(2-Aminoquinazolin-6-yl)-4-methyl-1-[4-(1,3-oxazol-2-yl)phenyl]pyridin-2-one | IC50 | 16.0 [1], 22.0 [2] |
| 7,8-Dihydroxy-5,6-dimethoxy-2-phenylchromen-4-one | IC50 | 500.0 [1], 7800.0 [2] |
| Flt-3 Inhibitor II | IC50 | 500.0 [1] |
| (2Z)-6-Hydroxy-2-(4-methoxybenzylidene)-1-benzofuran-3(2H)-one | IC50 | 1400.0 [1], 15600.0 [2] |
| 1-(4-(3-Amino-1H-indazol-4-yl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea | IC50 | 41.0 [1] |
| 1-(4-(3-Amino-1H-indazol-4-yl)phenyl)-3-m-tolylurea | IC50 | 17.0 [1] |
| 1-(4-(3-Amino-1H-indazol-4-yl)phenyl)-3-(4-fluoro-3-methylphenyl)urea | IC50 | 10.0 [1] |
| 2-Methyl-N-pyrimidin-5-yl-5-[[3-(trifluoromethyl)benzoyl]amino]benzamide | IC50 | 14.0 [1] |
| N-[4-[4-[[5-Tert-butyl-2-(3-methylphenyl)pyrazol-3-yl]carbamoylamino]anilino]quinazolin-6-yl]propanamide | IC50 | 21.9 [1], 155.0 [2] |
| 9-Ethyl-6,6-dimethyl-8-[4-(oxetan-3-yl)piperazin-1-yl]-11-oxo-5H-benzo[b]carbazole-3-carbonitrile | IC50 | 5000.0 [1] |
| Thienopyrimidine deriv. 74 | IC50 | 28.0 [1], 28.18 [2] |
| Thienopyrimidine deriv. 12 | IC50 | 83.0 [1], 83.18 [2] |
| Thienopyrimidine deriv. 17 | IC50 | 26.92 [1], 27.0 [2] |
| Thienopyrimidine deriv. 84 | IC50 | 37.0 [1], 37.15 [2] |
| Thienopyrimidine deriv. 86 | IC50 | 25.7 [1], 26.0 [2] |
| (1S)-2-(1H-Indol-3-YL)-1-[({5-[(E)-2-pyridin-4-ylvinyl]pyridin-3-YL}oxy)methyl]ethylamine | IC50 | 50000.0 [1] |
| N-(1,3-Benzodioxol-5-ylmethyl)-4-(6,7-dimethoxyquinazolin-4-yl)piperazine-1-carbothioamide | IC50 | 220.0 [1], 1800.0 [2] |
| Methanesulfonic acid;N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-(piperazin-1-ylmethyl)benzamide | IC50 | 293.0 [1], 342.0 [2] |
| 1-(4-(3-Amino-1H-indazol-4-yl)phenyl)-3-(3-bromophenyl)urea | IC50 | 69.0 [1] |
| 1-(4-(3-Amino-7-((4-methylpiperazin-1-yl)methyl)-1H-indazol-4-yl)phenyl)-3-m-tolylurea | IC50 | 290.0 [1] |
| 1-(4-(3-Amino-7-fluoro-1H-indazol-4-yl)phenyl)-3-m-tolylurea | IC50 | 5.0 [1] |
| 1-(4-(3-Amino-7-bromo-1H-indazol-4-yl)phenyl)-3-m-tolylurea | IC50 | 39.0 [1] |
| 1-(4-(3-Amino-1H-indazol-4-yl)phenyl)-3-(3-ethylphenyl)urea | IC50 | 42.0 [1] |
| 1-(4-(3-Amino-7-(2-morpholinoethoxy)-1H-indazol-4-yl)phenyl)-3-m-tolylurea | IC50 | 50.0 [1] |
| 1-(4-(3-Amino-1H-indazol-4-yl)phenyl)-3-(3-chlorophenyl)urea | IC50 | 13.0 [1] |
| 1-(4-(3-Amino-7-(2-(2-oxopyrrolidin-1-yl)ethoxy)-1H-indazol-4-yl)phenyl)-3-m-tolylurea | IC50 | 53.0 [1] |
| 4-(6,7-Dimethoxy-9H-pyrimido[4,5-b]indol-4-yl)-N-[4-(pyrimidin-2-ylsulfamoyl)phenyl]piperazine-1-carbothioamide | IC50 | 28000.0 [1] |
| 1-[4-(3-Amino-1H-indazol-4-yl)phenyl]-3-thiophen-3-ylurea | IC50 | 42.0 [1] |
| 1-(4-(3-Amino-1H-indazol-4-yl)phenyl)-3-cyclopentylurea | IC50 | 850.0 [1] |